Insmed (NASDAQ:INSM) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.73) by 91.78 percent. This is a 96.47 percent increase over losses of $(1.70) per share from the same period last year. The company reported quarterly sales of $425.486 million which beat the analyst consensus estimate of $392.836 million by 8.31 percent. This is a 296.11 percent increase over sales of $107.415 million the same period last year.